Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma

A. Basit Khan; Collin W. English; William C. Chen; Prazwal Athukuri; James C. Bayley; Vicky L. Brandt; Arya Shetty; Caroline C. Hadley; Abrar Choudhury; Hsiang Chih Lu; Arif O. Harmanci; Akdes S. Harmanci; Stephen T. Magill; David R. Raleigh; Tiemo J. Klisch; Akash J. Patel

doi:10.1007/s00401-023-02543-7

Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma

A. Basit Khan, Collin W. English, William C. Chen, Prazwal Athukuri, James C. Bayley, Vicky L. Brandt, Arya Shetty, Caroline C. Hadley, Abrar Choudhury, Hsiang Chih Lu, Arif O. Harmanci, Akdes S. Harmanci, Stephen T. Magill, David R. Raleigh, Tiemo J. Klisch^*, Akash J. Patel^*

^*Corresponding author for this work

Neurological Surgery

Research output: Contribution to journal › Letter › peer-review

15 Scopus citations

Original language	English (US)
Pages (from-to)	501-503
Number of pages	3
Journal	Acta Neuropathologica
Volume	145
Issue number	4
DOIs	https://doi.org/10.1007/s00401-023-02543-7
State	Published - Apr 2023

Funding

This work was supported by the NINDS (K08NS102474 to AJP and R25NS070694 to JCB), the Roderick D. MacDonald Fund (AJP), the Hamill Foundation (AJP), the Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Cancer Center (STM), P50 CA097257 (WCC, DRR), R01 CA262311 (DRR), F32 CA213944 (STM), F30 CA246808 and T32 GM007618 (AC), a UCSF Catalyst Program Award (WCC, DRR), and the UCSF Wolfe Meningioma Program Project (DRR). This work was also supported by a Conquer Cancer Herman H. Freckman, MD, Endowed Young Investigator Award from the American Society of Clinical Oncology (WCC). Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of Conquer Cancer or the American Society of Clinical Oncology.

ASJC Scopus subject areas

Clinical Neurology
Cellular and Molecular Neuroscience
Pathology and Forensic Medicine

Access to Document

10.1007/s00401-023-02543-7

Cite this

Khan, A. B., English, C. W., Chen, W. C., Athukuri, P., Bayley, J. C., Brandt, V. L., Shetty, A., Hadley, C. C., Choudhury, A., Lu, H. C., Harmanci, A. O., Harmanci, A. S., Magill, S. T., Raleigh, D. R., Klisch, T. J., & Patel, A. J. (2023). Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma. Acta Neuropathologica, 145(4), 501-503. https://doi.org/10.1007/s00401-023-02543-7

@article{2084577844124decadd02504fdbe9929,

title = "Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma",

author = "Khan, {A. Basit} and English, {Collin W.} and Chen, {William C.} and Prazwal Athukuri and Bayley, {James C.} and Brandt, {Vicky L.} and Arya Shetty and Hadley, {Caroline C.} and Abrar Choudhury and Lu, {Hsiang Chih} and Harmanci, {Arif O.} and Harmanci, {Akdes S.} and Magill, {Stephen T.} and Raleigh, {David R.} and Klisch, {Tiemo J.} and Patel, {Akash J.}",

note = "Funding Information: This work was supported by the NINDS (K08NS102474 to AJP and R25NS070694 to JCB), the Roderick D. MacDonald Fund (AJP), the Hamill Foundation (AJP), the Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Cancer Center (STM), P50 CA097257 (WCC, DRR), R01 CA262311 (DRR), F32 CA213944 (STM), F30 CA246808 and T32 GM007618 (AC), a UCSF Catalyst Program Award (WCC, DRR), and the UCSF Wolfe Meningioma Program Project (DRR). This work was also supported by a Conquer Cancer Herman H. Freckman, MD, Endowed Young Investigator Award from the American Society of Clinical Oncology (WCC). Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of Conquer Cancer or the American Society of Clinical Oncology. ",

year = "2023",

month = apr,

doi = "10.1007/s00401-023-02543-7",

language = "English (US)",

volume = "145",

pages = "501--503",

journal = "Acta Neuropathologica",

issn = "0001-6322",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "4",

}

Khan, AB, English, CW, Chen, WC, Athukuri, P, Bayley, JC, Brandt, VL, Shetty, A, Hadley, CC, Choudhury, A, Lu, HC, Harmanci, AO, Harmanci, AS, Magill, ST, Raleigh, DR, Klisch, TJ & Patel, AJ 2023, 'Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma', Acta Neuropathologica, vol. 145, no. 4, pp. 501-503. https://doi.org/10.1007/s00401-023-02543-7

TY - JOUR

T1 - Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma

AU - Khan, A. Basit

AU - English, Collin W.

AU - Chen, William C.

AU - Athukuri, Prazwal

AU - Bayley, James C.

AU - Brandt, Vicky L.

AU - Shetty, Arya

AU - Hadley, Caroline C.

AU - Choudhury, Abrar

AU - Lu, Hsiang Chih

AU - Harmanci, Arif O.

AU - Harmanci, Akdes S.

AU - Magill, Stephen T.

AU - Raleigh, David R.

AU - Klisch, Tiemo J.

AU - Patel, Akash J.

N1 - Funding Information: This work was supported by the NINDS (K08NS102474 to AJP and R25NS070694 to JCB), the Roderick D. MacDonald Fund (AJP), the Hamill Foundation (AJP), the Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Cancer Center (STM), P50 CA097257 (WCC, DRR), R01 CA262311 (DRR), F32 CA213944 (STM), F30 CA246808 and T32 GM007618 (AC), a UCSF Catalyst Program Award (WCC, DRR), and the UCSF Wolfe Meningioma Program Project (DRR). This work was also supported by a Conquer Cancer Herman H. Freckman, MD, Endowed Young Investigator Award from the American Society of Clinical Oncology (WCC). Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of Conquer Cancer or the American Society of Clinical Oncology.

PY - 2023/4

Y1 - 2023/4

UR - http://www.scopus.com/inward/record.url?scp=85147309566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147309566&partnerID=8YFLogxK

U2 - 10.1007/s00401-023-02543-7

DO - 10.1007/s00401-023-02543-7

M3 - Letter

C2 - 36729132

AN - SCOPUS:85147309566

SN - 0001-6322

VL - 145

SP - 501

EP - 503

JO - Acta Neuropathologica

JF - Acta Neuropathologica

IS - 4

ER -

Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this